drugset / Trial / NCT02113293

CyclASol® Phase 1 Study

NCT02113293

Phase 1 Completed 18 enrolled Novaliq GmbH
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is intended to investigate the tolerability and the safety of Cyclosporine A containing CyclASol® eye drops compared to Placebo (vehicle) in a cohort of healthy volunteers. Subjects will be randomly assigned to dosing with CyclASol® eye drops or Placebo (vehicle) in the first part (first period) of the study, and switched to the alternative dosing in the second part (second period) of the study. An ophthalmological assessment of the eyes will be performed, and a questionnaire will be issued in the beginning and after each dosing. Additionally physical examinations, safety laboratory and ECGs will be performed, and blood samples will be analyzed for Cyclosporine A and Placebo (vehicle).

Timeline

Start
2014-03
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclosporine Peptide Topical

Indications

No indication recorded.